Highlights Devonian Health Group Inc.

Equities

GSD

CA2518341078

Market Closed - Toronto S.E. Other stock markets 11:26:55 2024-06-06 am EDT			5-day change	1st Jan Change
0.14 ^CAD	0.00%		-6.67%	-3.45%

Jun. 03	Devonian Health Group Founder Assumes Chair, COO Roles	MT
Jun. 03	Devonian Health Group Inc. Appoints André P. Boulet to Chairman of the Board and Chief Operating Officer	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Devonian Health Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	Mar. 28	CI
Devonian Health Group Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023	Dec. 22	CI
Devonian Health Group Inc. Reports Earnings Results for the Full Year Ended July 31, 2023	Nov. 28	CI
Devonian Health Group Inc. Files Patent Cooperation Treaty Application for Thykamine?? in Wound Healing	Nov. 08	CI
Devonian Health Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	23-06-28	CI
Devonian Health Group Announces Presentation of ThykamineTM Efficacy Results in Atopic Dermatitis at the World Congress of Dermatology and Provides ThykamineTM Clinical Development Program Update	23-05-16	CI
Devonian Health Group Announces the Appointment of New Board Members	23-05-12	CI
Devonian Health Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	23-03-24	CI
Devonian Health Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	23-03-24	CI
Devonian Health Group Inc. Reports Earnings Results for the First Quarter Ended October 31, 2022	22-12-22	CI
Devonian Health Group Inc. Reports Earnings Results for the Full Year Ended July 31, 2022	22-11-28	CI
Devonian Health Group Inc. to Present ThykamineTM Phase 2 Clinical Results at the 6th Dermatology Drug Development Summit for Inflammatory Skin Diseases	22-10-12	CI
Devonian Health Group Announces Peer-Reviewed Publication of Thykamine™ Positive Phase 2 Clinical Trial Results in Journal of Drugs in Dermatology	22-10-06	CI
Devonian Health Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2022	22-06-22	CI
Devonian Health Group Announces the Journal of Drugs in Dermatology Acceptance for Publication of Thykamine™ Positive Phase 2 Clinical Trial Results in Atopic Dermatitis	22-05-26	CI
Devonian Health Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2022	22-03-31	CI
Devonian Health Group Applies for OTCQB Listing	22-01-11	MT
Devonian Health Group Inc. Reports Earnings Results for the First Quarter Ended October 31, 2021	21-12-22	CI
Devonian Health Group Inc. Reports Earnings Results for the Full Year Ended July 31, 2021	21-11-26	CI
Devonian Health : Announces Distribution Agreement for Anti-aging Products in Middle East Countries	21-08-31	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Devonian Health Group Inc.

Equities

GSD

CA2518341078

Highlights

Filters